All Trials

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic NSCLC (squamous or non-squamous), including both first-line AGA-negative and previously treated patients (with genotype-specific prior therapy, e.g., post–third-gen EGFR TKI), receive the HER3-directed topoisomerase I ADC BNT326 combined with the PD-L1/VEGF-A bispecific antibody BNT327, with arms also testing each agent alone and standard-of-care comparators by PD-L1 status. Excludes prior HER3/topo I ADC exposure (with limited exceptions), uncontrolled ILD/pneumonitis, active CNS disease needing steroids/anticonvulsants, significant effusions, and high-grade prior irAEs leading to ICI discontinuation.

ClinicalTrials.gov ID: NCT07111520

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic NSCLC (ECOG 0–1), excluding EGFR/ALK alterations, receive intratumoral tolododekin alfa (ANK-101), an anchored IL‑12 designed for localized immune activation, combined with an anti–PD-1/PD-L1 antibody. Includes two cohorts: post–PD-1/PD-L1 and platinum–pretreated patients receiving tolododekin alfa plus cetrelimab, and treatment‑naïve patients receiving tolododekin alfa plus investigator’s choice of approved PD-1/PD-L1 inhibitor; mandatory fresh biopsies.

ClinicalTrials.gov ID: NCT07027514

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with de novo, high-volume metastatic hormone-sensitive prostate adenocarcinoma on ADT (with or without recent darolutamide or abiraterone) and no prior docetaxel are treated with xaluritamig plus either darolutamide or abiraterone. Xaluritamig (AMG 509) is an investigational STEAP1×CD3 bispecific T‑cell engager; the study assesses safety and preliminary activity of these combinations.

ClinicalTrials.gov ID: NCT07140900

A Phase Ib Clinical Trial to Optimize Risk Benefit of REGN5678 (PSMAxCD28 Bispecific Antibody) Plus Cemiplimab (Anti-PD-1 Monoclonal Antibody) in Patients With Metastatic Castration-resistant Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Men with metastatic castration‑resistant prostate cancer progressing after ≥2 prior systemic regimens (including a next‑generation AR pathway inhibitor), ECOG 0–1, and adequate organ function; prior PSMA‑targeted therapy and immunotherapy allowed. Treatment is REGN5678 (nezastomig), a PSMA×CD28 T‑cell costimulatory bispecific antibody with a weekly lead‑in then q3w dosing, combined q3w with the PD‑1 inhibitor cemiplimab.

ClinicalTrials.gov ID: NCT06826768

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma (taxane-naive in the mCRPC setting) after 1–2 AR pathway inhibitors are randomized to ifinatamab deruxtecan (I-DXd, a B7-H3–targeting antibody–drug conjugate delivering a topoisomerase I inhibitor) alone or combined with MK-5684 (opevesostat, a CYP11A1 inhibitor suppressing steroidogenesis) or an ARPI (abiraterone or enzalutamide) versus docetaxel. Key exclusions include prior ILD/pneumonitis and prior taxane for mCRPC; endpoints include safety, PSA50, and radiographic efficacy.

ClinicalTrials.gov ID: NCT06863272

A Phase 2 Pragmatic Clinical Trial to Evaluate Administration of Cancer Therapy in the Patients' Homes Versus in Clinic in Black Men With Advanced or Metastatic Prostate Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Black or African American men with locally advanced/high-risk, biochemically recurrent, or metastatic prostate cancer receive standard therapies first in clinic then at home with remote monitoring to compare safety and patient-centered outcomes. Eligible regimens for home administration include ADT (leuprolide, degarelix), cabazitaxel, pembrolizumab, and bone-modifying agents (zoledronic acid, denosumab); oral agents like second-generation antiandrogens or PARP inhibitors may be continued but oral-only regimens are excluded.

ClinicalTrials.gov ID: NCT07073794

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory DLL3-expressing small cell lung cancer after platinum chemotherapy and PD-1/PD-L1 therapy receive IDE849, a DLL3-directed antibody–drug conjugate delivering a topoisomerase I inhibitor. Open-label dose escalation and expansion enroll ECOG 0–1 patients with measurable disease; key exclusions include active/untreated CNS metastases and prior DLL3 or TOP1 inhibitor ADC exposure.

ClinicalTrials.gov ID: NCT07174583

Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent high-grade uterine/endometrial cancers (FIGO grade 3 endometrioid, serous, mixed high-grade, or carcinosarcoma) after platinum, ECOG 0–2, measurable disease, and prior HER2- or immune-therapy as appropriate, receive paclitaxel plus zanzalintinib (XL092), an oral multi-targeted TKI inhibiting VEGFR2, MET, and TAM kinases, with maintenance zanzalintinib for responders/stable disease. Excludes prior TKIs/bevacizumab, uncontrolled CV disease, high-risk bleeding/GI conditions, and untreated/unstable CNS disease.

ClinicalTrials.gov ID: NCT06795009

ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic breast cancer on ongoing fam-trastuzumab deruxtecan (Enhertu) after 3–4 cycles and experiencing clinician-identified fatigue are randomized to a 12-week, home-based aerobic plus resistance exercise program versus usual care. Enhertu, an anti-HER2 antibody–drug conjugate delivering a topoisomerase I inhibitor to HER2-expressing cells, continues per standard care; the study tests whether structured exercise reduces cancer-related fatigue.

ClinicalTrials.gov ID: NCT07203378

A Phase Ia/Ib Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Patients With Locally Advanced Or Metastatic ER-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After CDK4/6 Inhibitor Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults with locally advanced/metastatic ER-positive, HER2-negative breast cancer with RECIST-evaluable disease and ECOG 0–1 who progressed during/after prior CDK4/6 inhibitor therapy (no visceral crisis requiring urgent chemotherapy), this study tests oral GDC-0587, an investigational selective CDK4 inhibitor, as monotherapy or combined with giredestrant, an oral selective estrogen receptor degrader. Key aims are to define safety/PK and recommended doses, with a cohort assessing food and proton pump inhibitor (omeprazole) effects on GDC-0587 exposure.

ClinicalTrials.gov ID: NCT07214662